Corona Remedies Ltd (CORONA) — shareholding pattern, promoter holding, financials and share price
About Corona Remedies Ltd (CORONA)
Corona Remedies Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CORONA and on the BSE under scrip code 544644. Its ISIN is INE02ZQ01018.
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. [1]
CORONA Remedies Limited is an India‑focused, branded pharmaceutical company that develops, manufactures and markets formulations across women’s healthcare, cardio‑diabeto, pain management, urology and other therapies, operating manufacturing plants in Solan (Himachal Pradesh) and Bhayla/Ahmedabad (Gujarat) with DSIR R&D and multiple GMP certifications supporting domestic and export ambitions.
Financial momentum is healthy: Q3 FY26 revenue of INR 342 crore (+15% YoY) and 9M FY26 revenue of INR 1,050 crore (+16.3%), with EBITDA margins improving to 24.3% in Q3 and 22.0% for 9M, and adjusted PAT up 23.7% in Q3 and 30.7% for 9M, reflecting operating leverage and strong brand economics.
Listed peers in Pharmaceuticals: Concord Biotech Ltd, Marksans Pharma Ltd, Shilpa Medicare Ltd, Viyash Scientific Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹2,037.35 a share on 10 Jul 2026, Corona Remedies Ltd (CORONA) was valued at a price-to-earnings ratio of 67.31x against an industry P/E of 36.41x and a price-to-book of 16.68x on a book value of ₹122.12 per share as of Mar 2026. Solomo computes return on equity of 24.79% and return on capital employed of 27.13% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 67.31x
- Industry P/E
- 36.41x
- P/B
- 16.68x
- EPS (TTM)
- ₹30.27
- Book value / share
- ₹122.12
- ROE
- 24.79%
- ROCE
- 27.13%
- ROA
- 15.36%
- Debt / equity
- 0.22x
- Dividend yield
- 0.49%
- EBITDA margin
- 20.33%
- 52-week range
- ₹1,336.95 – ₹2,097.35
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Corona Remedies Ltd (CORONA) reported revenue of ₹1,403 crore, net profit of ₹185 crore and earnings per share of ₹30.27. That compares with revenue of ₹1,196 crore and net profit of ₹149 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹353 crore and net profit ₹45 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 884 | 1,014 | 1,196 | 1,403 |
| Net profit (₹ cr) | 85 | 90 | 149 | 185 |
| EPS (₹) | 13.89 | 14.8 | 24.43 | 30.27 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 16.65% | 17.28% |
| Profit growth | 29.71% | 23.88% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 69% of Corona Remedies Ltd (CORONA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 3.63% and domestic institutional investors (DII) hold 12.9%. Market capitalisation was ₹12,460 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2025.
Largest disclosed public shareholders in Jun 2026: SEPIA INVESTMENTS LIMITED 12.68%, INVESCO INDIA SMALLCAP FUND 5.06%, HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUND 4.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 69% | - | 3.63% | 12.9% | 31% |
| Mar 2026 | 69% | - | 2.25% | 7.02% | 31% |
| Dec 2025 | 69% | - | 1.84% | 6.76% | 31% |